ProCE Banner Activity

Experts Answer Key Questions on Managing Anemia in Patients With Lower-Risk MDS

Clinical Thought

How confident are you managing anemia in patients with lower-risk MDS? Read expert responses to questions on this topic from a live webinar discussion.

Released: July 08, 2024

Expiration: July 07, 2025

Share

Faculty

Rami Komrokji

Rami Komrokji, MD

Vice Chair of Malignant Hematology Department
Senior Member and Professor of Oncologic Sciences
H. Lee Moffitt Cancer Center
University of South Florida
Tampa, Florida

Maximilian Stahl

Maximilian Stahl, MD

Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Amer Zeidan

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Disclosure

Primary Author

Rami Komrokji, MD

Vice Chair of Malignant Hematology Department
Senior Member and Professor of Oncologic Sciences
H. Lee Moffitt Cancer Center
University of South Florida
Tampa, Florida

Rami Komrokji, MD: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, DSI, Genentech, Geron, Jazz, PharmaEssentia, Rigel, Servier, Sobi, Sumitomo; researcher: Bristol Myers Squibb.

Maximilian Stahl, MD

Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Maximilian Stahl, MD: consultant/advisor/speaker: Bristol Myers Squibb, Curis, GlaxoSmithKline, Kymera, Rigel Pharmaceuticals, Sierra Oncology, Sobi.

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Amer M. Zeidan, MBBS, MHS: researcher (paid to institution): AbbVie, Aprea, Astex, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, Cura, Foran, Geron, Incyte, Kura, MedImmune/AstraZeneca, Novartis, Pfizer, Shattuck Labs, Takeda; consultant/advisor/speaker: AbbVie, Agios, ALX Oncology, Amgen, Astellas, BeyondSpring, BioCryst, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, Chiesi, Daiichi Sankyo, Epizyme, Genentech, Geron, Gilead, Incyte, Ionis, Janssen, Jazz, Kura, Mendus, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Seattle Genetics, Schrodinger, Servier, Syndax, Syros, Taiho, Takeda, Tyme, Zentalis; other financial or material support: AbbVie, ALX Oncology, BioCryst, Celgene/Bristol Myers Squibb, Geron, Gilead, Kura, Novartis, Syros.